HEPCIDIN MIMETIC: RUSFERTIDE (PTG-300) & ORAL IL-23R ANTAGONIST (PN-235, JNJ-77242113)

PROGRAMS CANDIDATES STUDY PHASE 1 PHASE 2 PHASE 3 KEY MILESTONES
HEMATOLOGY & BLOOD DISORDERS
Rusfertide
(PTG-300)
Hepcidin
Mimetic

Takeda Logo		 Rusfertide
(PTG-300)		 VERIFY
PV Ph3, n~293
 • 32-Wk Primary/Key Secondary EPs
REVIVE
PV Ph2, n=70, 40 wk study +3yr OLE
 • Study completed; OLE ongoing
THRIVE
PV Ph2 2 yr LTE, n=46
 • Ongoing; for REVIVE patients in OLE
PACIFIC
PV Ph2 Elevated Hct (>48%), n=20
• Completed
INFLAMMATORY & IMMUNOMODULATORY DISEASES
Oral IL-23R
Antagonist
(Partnered)
Janssen Logo		 JNJ-2113
(PN-235) 		FRONTIER 1 & 2
Psoriasis Ph2b, n=255&227
• Completed
ICONIC-LEAD
Psoriasis Ph3, n=684
• 16-Wk Primary EP 1
ICONIC-TOTAL
Psoriasis Ph3, n=311
• 16-Wk Primary EP 2
ICONIC-ADVANCE
Psoriasis 1 Ph 3, n=774
• 16-Wk Co-Primary EP 3
ICONIC-ADVANCE
Psoriasis 2 Ph 3, n~731
• 16-Wk Co-Primary EP 4
Pustular/Erythrodermic
Psoriasis Ph 3, n~19
• Ongoing 5
ICONIC-PsA 2
Psoriasis Ph 3, n~750
• Ph3 study initiated 6
ULCERATIVE COLITIS (UC)
ANTHEM Ph2b, n=252
 • 12-Wk Primary EP 7
DISCOVERY
Discovery
Oral IL-17 8
• Phase 1 initiation ~Q4 ‘25
Oral Obesity
• Development candidate ~Q2 ‘25
Oral Hepcidin
• Development candidate ~Q4 ‘25

1 See clinicaltrials.gov NCT06095115

2 See clinicaltrials.gov NCT06095102
3 See clinicaltrials.gov NCT06143878

4 See clinicaltrials.gov NCT06220604

5 See clinicaltrials.gov NCT06295692

6 See clinicaltrials.gov NCT06807424
7 See clinicaltrials.gov NCT06049017

8 Development Candidate: ready for IND enabling studies